278 related articles for article (PubMed ID: 33039944)
1. Shorter infusion time of ocrelizumab: Results from the randomized, double-blind ENSEMBLE PLUS substudy in patients with relapsing-remitting multiple sclerosis.
Hartung HP; Berger T; Bermel RA; Brochet B; Carroll WM; Holmøy T; Karabudak R; Killestein J; Nos C; Patti F; Ross AP; Vanopdenbosch L; Vollmer T; Buffels R; Garas M; Kadner K; Manfrini M; Wang Q; Freedman MS
Mult Scler Relat Disord; 2020 Nov; 46():102492. PubMed ID: 33039944
[TBL] [Abstract][Full Text] [Related]
2. Ocrelizumab shorter infusion: Primary results from the ENSEMBLE PLUS substudy in patients with MS.
Hartung HP;
Neurol Neuroimmunol Neuroinflamm; 2020 Sep; 7(5):. PubMed ID: 32503093
[TBL] [Abstract][Full Text] [Related]
3. ENSEMBLE PLUS: final results of shorter ocrelizumab infusion from a randomized controlled trial.
Hartung HP; Berger T; Bermel RA; Brochet B; Carroll WM; Holmøy T; Karabudak R; Killestein J; Nos C; Patti F; Perrin Ross A; Vanopdenbosch L; Vollmer T; Buffels R; Garas M; Kadner K; Manfrini M; Wang Q; Freedman MS
J Neurol; 2024 Apr; ():. PubMed ID: 38649522
[TBL] [Abstract][Full Text] [Related]
4. Ocrelizumab infusion experience in patients with relapsing and primary progressive multiple sclerosis: Results from the phase 3 randomized OPERA I, OPERA II, and ORATORIO studies.
Mayer L; Kappos L; Racke MK; Rammohan K; Traboulsee A; Hauser SL; Julian L; Köndgen H; Li C; Napieralski J; Zheng H; Wolinsky JS
Mult Scler Relat Disord; 2019 May; 30():236-243. PubMed ID: 30844611
[TBL] [Abstract][Full Text] [Related]
5. Safety results of administering ocrelizumab per a shorter infusion protocol in patients with primary progressive and relapsing multiple sclerosis.
Vollmer TL; Cohen JA; Alvarez E; Nair KV; Boster A; Katz J; Pardo G; Pei J; Raut P; Merchant S; MacLean E; Pradhan A; Moss B
Mult Scler Relat Disord; 2020 Nov; 46():102454. PubMed ID: 33045496
[TBL] [Abstract][Full Text] [Related]
6. Comparing infusion-related reactions of the first full dose (600 mg) biosimilar ocrelizumab administration with the standard divided protocol in multiple sclerosis patients: a randomized controlled trial study.
Abbasi Kasbi N; Ghadiri F; Sahraian MA; Nahayati MA; Moghadasi AN; Langroodi HG; Poursadeghfard M; Hosseini S; Heidari H; Baghbanian SM; Kamali H; Ameli Z; Shahmohammadi S; Navardi S
Acta Neurol Belg; 2024 Feb; 124(1):205-212. PubMed ID: 37715074
[TBL] [Abstract][Full Text] [Related]
7. Safety evaluation of shorter infusion for ocrelizumab in a substudy of the Phase IIIb CHORDS trial.
Bermel RA; Waubant E; Pardo G; Bass A; Repovic P; Newsome S; Lindsey JW; Kile D; Pradhan A; Musch B; Zabeti A
Ann Clin Transl Neurol; 2021 Mar; 8(3):711-715. PubMed ID: 33621404
[TBL] [Abstract][Full Text] [Related]
8. Ocrelizumab: A Review in Multiple Sclerosis.
Lamb YN
Drugs; 2022 Feb; 82(3):323-334. PubMed ID: 35192158
[TBL] [Abstract][Full Text] [Related]
9. Efficacy, safety and patient reported outcomes in patients with active relapsing multiple sclerosis treated with ocrelizumab: Final results from the PRO-MSACTIVE study.
Manchon E; Laplaud D; Vukusic S; Labauge P; Moreau T; Kobelt G; Grouin JM; Lotz M; Pau D; Christine LF
Mult Scler Relat Disord; 2022 Dec; 68():104109. PubMed ID: 36007299
[TBL] [Abstract][Full Text] [Related]
10. Safety and patient experience with at-home infusion of ocrelizumab for multiple sclerosis.
Barrera B; Simpson H; Engebretson E; Sillau S; Valdez B; Parra-González J; Winger RC; Epperson LA; Banks A; Pierce K; Spotts M; O'Gean K; Alvarez E; Gross R; Piquet AL; Schreiner T; Corboy JR; Pei J; Vollmer TL; Nair KV
Ann Clin Transl Neurol; 2023 Apr; 10(4):579-588. PubMed ID: 36811392
[TBL] [Abstract][Full Text] [Related]
11. Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial.
Kappos L; Li D; Calabresi PA; O'Connor P; Bar-Or A; Barkhof F; Yin M; Leppert D; Glanzman R; Tinbergen J; Hauser SL
Lancet; 2011 Nov; 378(9805):1779-87. PubMed ID: 22047971
[TBL] [Abstract][Full Text] [Related]
12. Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis.
Hauser SL; Bar-Or A; Comi G; Giovannoni G; Hartung HP; Hemmer B; Lublin F; Montalban X; Rammohan KW; Selmaj K; Traboulsee A; Wolinsky JS; Arnold DL; Klingelschmitt G; Masterman D; Fontoura P; Belachew S; Chin P; Mairon N; Garren H; Kappos L;
N Engl J Med; 2017 Jan; 376(3):221-234. PubMed ID: 28002679
[TBL] [Abstract][Full Text] [Related]
13. Ocrelizumab: A New B-cell Therapy for Relapsing Remitting and Primary Progressive Multiple Sclerosis.
Stahnke AM; Holt KM
Ann Pharmacother; 2018 May; 52(5):473-483. PubMed ID: 29232960
[TBL] [Abstract][Full Text] [Related]
14. Infusion-related reactions during Natalizumab treatment: Do we still need a post-infusion observation period?
Sacco R; Disanto G; Maraffi I; Candrian U; Kamm CP; Rossi S; Schwegler G; Gallo A; Gobbi C; Zecca C
Mult Scler Relat Disord; 2020 Feb; 38():101523. PubMed ID: 31743848
[TBL] [Abstract][Full Text] [Related]
15. Relapsing-remitting and primary progressive multiple sclerosis treated with ocrelizumab: A comparative study.
Rodriguez de Antonio LA; Cuberta-Gonzalez I; Garcia-Castañon I; Oreja-Guevara C
Mult Scler Relat Disord; 2023 Jan; 69():104441. PubMed ID: 36493559
[TBL] [Abstract][Full Text] [Related]
16. Ocrelizumab exposure in relapsing-remitting multiple sclerosis: 10-year analysis of the phase 2 randomized clinical trial and its extension.
Kappos L; Traboulsee A; Li DKB; Bar-Or A; Barkhof F; Montalban X; Leppert D; Baldinotti A; Schneble HM; Koendgen H; Sauter A; Wang Q; Hauser SL
J Neurol; 2024 Feb; 271(2):642-657. PubMed ID: 37906326
[TBL] [Abstract][Full Text] [Related]
17. Acute pancreatitis after ocrelizumab treatment for relapsing remitting multiple sclerosis.
Adamec I; Reiner Ž; Pećin I; Šućur N; Godan Hauptman A; Barun B; Gabelić T; Habek M
Mult Scler Relat Disord; 2020 Oct; 45():102381. PubMed ID: 32653735
[TBL] [Abstract][Full Text] [Related]
18. Long-term follow-up from the ORATORIO trial of ocrelizumab for primary progressive multiple sclerosis: a post-hoc analysis from the ongoing open-label extension of the randomised, placebo-controlled, phase 3 trial.
Wolinsky JS; Arnold DL; Brochet B; Hartung HP; Montalban X; Naismith RT; Manfrini M; Overell J; Koendgen H; Sauter A; Bennett I; Hubeaux S; Kappos L; Hauser SL
Lancet Neurol; 2020 Dec; 19(12):998-1009. PubMed ID: 33129442
[TBL] [Abstract][Full Text] [Related]
19. Fast and safe: Optimising multiple sclerosis infusions during COVID-19 pandemic.
Rath L; Bui MV; Ellis J; Carey J; Baker J; Taylor L; Fernando H; Taylor N; Savage P; Richards J; Zhong M; Kalincik T; Skibina O; Wesselingh R; Nguyen AL; Monif M; Butzkueven H; van der Walt A
Mult Scler Relat Disord; 2021 Jan; 47():102642. PubMed ID: 33321356
[TBL] [Abstract][Full Text] [Related]
20. Comparing the Risk of Infusion-Related Reactions and Tolerability in Patients Given Cetirizine or Diphenhydramine Prior to Ocrelizumab Infusion (PRECEPT).
Smoot K; Marginean H; Gervasi-Follmar T; Chen C
Medicina (Kaunas); 2024 Apr; 60(4):. PubMed ID: 38674305
[No Abstract] [Full Text] [Related]
[Next] [New Search]
